Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Other Non-Current Liabilities (2022 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities rose 102.11% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, up 102.11% year-over-year, with the annual reading at $1.2 million for FY2025, N/A changed from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $1.2 million at Neuphoria Therapeutics, down from $8.1 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $8.1 million in Q3 2025, with the low at $3437.0 in Q3 2024.
  • Average Other Non-Current Liabilities over 4 years is $1.4 million, with a median of $536041.5 recorded in 2024.
  • The sharpest move saw Other Non-Current Liabilities soared 99.81% in 2023, then soared 235344.22% in 2025.
  • Over 4 years, Other Non-Current Liabilities stood at $7492.2 in 2022, then skyrocketed by 99.81% to $14969.9 in 2023, then soared by 3776.42% to $580298.0 in 2024, then skyrocketed by 102.11% to $1.2 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $1.2 million, $8.1 million, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.